BMC Cancer | |
Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer | |
Research Article | |
Jenny Brändstedt1  Karin Jirstrom2  Mathias Uhlén3  Fredrik Pontén4  Donal J Brennan5  Elton Rexhepaj6  Darran P O'Connor6  William M Gallagher6  Michael Foley7  Colm O'Herlihy7  | |
[1] Center for Molecular Pathology, Department of Laboratory Medicine, Malmö University Hospital, Lund University, Malmö, Sweden;Center for Molecular Pathology, Department of Laboratory Medicine, Malmö University Hospital, Lund University, Malmö, Sweden;CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden;Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden;Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden;Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland;UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland;UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland;UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland; | |
关键词: Overall Survival; Ovarian Cancer; Statin; Epithelial Ovarian Cancer; Recurrence Free Survival; | |
DOI : 10.1186/1471-2407-10-125 | |
received in 2009-09-07, accepted in 2010-04-01, 发布年份 2010 | |
来源: Springer | |
【 摘 要 】
BackgroundOur group previously reported that tumour-specific expression of the rate-limiting enzyme in the mevalonate pathway, 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR) is associated with more favourable tumour parameters and a good prognosis in breast cancer. In the present study, the prognostic value of HMG-CoAR expression was examined in tumours from a cohort of patients with primary epithelial ovarian cancer.MethodsHMG-CoAR expression was assessed using immunohistochemistry (IHC) on tissue microarrays (TMA) consisting of 76 ovarian cancer cases, analysed using automated algorithms to develop a quantitative scoring model. Kaplan Meier analysis and Cox proportional hazards modelling were used to estimate the risk of recurrence free survival (RFS).ResultsSeventy-two tumours were suitable for analysis. Cytoplasmic HMG-CoAR expression was present in 65% (n = 46) of tumours. No relationship was seen between HMG-CoAR and age, histological subtype, grade, disease stage, estrogen receptor or Ki-67 status. Patients with tumours expressing HMG-CoAR had a significantly prolonged RFS (p = 0.012). Multivariate Cox regression analysis revealed that HMG-CoAR expression was an independent predictor of improved RFS (RR = 0.49, 95% CI (0.25-0.93); p = 0.03) when adjusted for established prognostic factors such as residual disease, tumour stage and grade.ConclusionHMG-CoAR expression is an independent predictor of prolonged RFS in primary ovarian cancer. As HMG-CoAR inhibitors, also known as statins, have demonstrated anti-neoplastic effects in vitro, further studies are required to evaluate HMG-CoAR expression as a surrogate marker of response to statin treatment, especially in conjunction with current chemotherapeutic regimens.
【 授权许可】
CC BY
© Brennan et al; licensee BioMed Central Ltd. 2010
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202311106985059ZK.pdf | 3514KB | download |
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
- [27]
- [28]
- [29]
- [30]
- [31]
- [32]
- [33]
- [34]
- [35]
- [36]
- [37]
- [38]
- [39]